Statement of Changes in Beneficial Ownership (4)
May 18 2021 - 7:02PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
HANNAH ALISON L. |
2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC
[
RIGL
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD. |
3. Date of Earliest Transaction
(MM/DD/YYYY)
5/14/2021 |
(Street)
SAN FRANCISCO, CA 94080
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | $3.71 | 5/14/2021 | | A | | 80000 | | (1) | 5/14/2031 | Common Stock | 80000 | $0 | 80000 | D | |
Explanation of Responses: |
(1) | The option shall vest in equal monthly installments over the shorter of three years from the date of grant or the period beginning on the date the Reporting Person was appointed to the Company's Board of Directors and ending on the date of the annual meeting at which the Reporting Person is first considered for election by the stockholders, provided that the Reporting Person continues to provide service. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
HANNAH ALISON L. RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SAN FRANCISCO, CA 94080 | X |
|
|
|
Signatures
|
/s/ Dolly Vance (Attorney-in-Fact) | | 5/18/2021 |
**Signature of Reporting Person | Date |
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From Apr 2023 to Apr 2024